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1. Introduction 
It is a daily challenge and the most common clinical practise to rule out possible bacterial 
infection in the ill neonate and especially in the preterm infant. Approximately half of all 
newborn infants admitted to the neonatal ward carry a diagnosis of “rule-out sepsis”, and 
diagnosis is often difficult as symptoms and signs of bacterial infection are subtle and 
nonspecific (1). The incidence of infection is higher in the neonatal period than at any other 
time of life, and factors that determine this increased susceptibility to bacterial infection 
include on the one hand the immaturity of the immune system with poor humoral 
responses to organisms (IgG and A), relatively poor neutrophil responses and complement 
activity, impaired macrophage function, and relatively poor T cell function, and on the other 
hand the exposure to microorganism from the maternal genital tract by ascending infections 
via the amniotic fluid or transplacental haematogenous spread. Additionally peripartum 
factors like trauma to skin or vessels during parturition or exposure to invasive obstetric 
procedures as well as portals of colonization and subsequent invasion (umbilicus, mucosal 
surfaces, eye, skin especially in very preterm infants) contribute to this increased risk for 
bacterial infection (2). Among extremely low birth weight infants at least 65% had one or 
more infections during their hospitalization in a National Institute of Child Health and 
Human Development Neonatal Research Network study including 6093 infants with follow-
up at 18 to 22 months of corrected gestational age. Compared with uninfected infants 
infected infants were significantly more likely to have adverse neurodevelopmental 
outcomes at follow-up, including cerebral palsy (range of significant odds ratios [ORs], 1.4-
1.7), low Bayley Scales of Infant Development II scores on the mental development index 
(ORs, 1.3-1.6) and psychomotor development index (ORs, 1.5-2.4), and vision impairment 
(ORs, 1.3-2.2). Infection in the neonatal period was also associated with impaired head 
growth, a known predictor of poor neurodevelopmental outcome (3). Reasons for the 
greater susceptibility to infection of preterm infants also include invasive procedures during 
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their stay at the NICU, prolonged artificial ventilation, intravenous feeding and antibiotic 
pressures. (2). The incidence is estimated to range from 1 to 5-8.1 per 1000 live births (2,4). 
The proportion of child deaths that occurs in the neonatal period (38% in the year 2000) is 
increasing, and the Millennium Development Goal for child survival cannot be met without 
substantial reductions in neonatal mortality. Every year an estimated 4 million babies die in 
the first four weeks of life (the neonatal period), and, globally, the main direct causes of 
neonatal death are estimated to be preterm birth (28%), severe infections (26%), and 
asphyxia (23%) (5). 
2. Pathophysiology of neonatal sepsis  
The immune system of the neonate is immature in both humoral and cell mediated defense 
with prematurity further increasing the physiological inadequacies of the immune system. 
Sepsis spreads easily to the various organ systems in the neonates and thus, often presents 
as a multiorgan dysfunctions syndrome. Infection initiates a complex immune process, 
which includes antigen detection, T-cell activation and proliferation, and release of 
cytokines. Cytokines are low molecular mass proteins, which mediate cell growth, 
inflammation, immunity, differentiation, migration and repair. They regulate the amplitude 
and the duration of the inflammatory response and include interleukins-6 and -8, 
interferons-γ, colony-stimulating factors, tumour necrosis factor-α and others. However in 
the setting of overwhelming sepsis as a result to the microbial insult, these cytokines give 
rise to what is described as the systemic inflammatory response syndrome, where the much 
of the damage paradoxically results from the host defences (e.g. cytokines) analogous to a 
chain reaction themselves. The neutrophil functions: adhesion, diapedesis, phagocytosis and 
degranulation are also of prime importance in the host defence mechanisms against 
bacterial and fungal pathogens. The proteolytic enzymes released by the neutrophils are 
also damaging to the host tissue. Thus, immunoglobulins and neutrophils are responsible 
for both host defence and damage in the setting of overwhelming neonatal sepsis (6).  
In 2005, definitions for paediatric infection, systemic inflammatory response syndrome, 
sepsis, severe sepsis, septic shock, and organ dysfunction were published that included term 
neonates of 0 to 7 days and newborns of 1 to 4 weeks of age (7). But one has to question why 
there are no criteria for the definition of sepsis and septic shock in preterm infants? The 
challenge of diagnosis of sepsis in the preterm infants is strongly associated with the 
immaturity of organ systems and transitional physiology. Suggested modifications of these 
definitions have recently been published (8) but still have to be proven in clinical trials (9). 
3. Immunoglobulins and the innate immune response 
Humoral immunity of the human newborn is provided primarily by maternal 
immunoglobulin G (IgG) transferred transplacentally, beginning at 8 to 10 weeks of 
gestation and accelerating during the last trimester. In a study to evaluate the role of 
maternally acquired antibody to native type III polysaccharide of group B Streptococcus as a 
determinant of susceptibility for infant systemic infection the authors found a significant 
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correlation with maternal antibody levels in 111 acutely ill infants (10). These data extended 
earlier observations suggesting the correlation between low levels of type-specific antibody 
in serum and risk for systemic infection in neonates. Premature infants, compared to full-
term infants, have lower levels of IgG at birth that further decreases during the first few 
weeks of life (11). The relative deficiency of humoral immunity in premature newborns 
might contribute to the inverse correlation of birth weight and rate of neonatal sepsis, with 
an 86-fold increased rate of sepsis in newborns of birth weight 600 to 999 grams compared to 
newborns of birth weight of more than 2500 grams (11). Ballow et al. (12) measured plasma 
immunoglobulin concentrations of premature infants of birth weight less than 1500 g 
longitudinally from birth to 10 months chronological age. During the first week of life 
plasma IgG levels correlated well with gestational age. At the age of three months mean 
plasma IgG levels were 60 mg/dl in infants of 25 to 28 weeks gestational age and 104 mg/dl 
in those of 29 to 32 weeks. Most infants remained hypogammaglobulinaemic at six months 
with 64% and 62%, respectively, of the infants having plasma IgG levels below 200 mg/dl. 
Plasma IgM concentrations were low in both groups during the first week of life (7.6 and 9.1 
mg/dl, respectively) and rose to 41.8 and 34.7 mg/dl, respectively, by eight to ten months of 
life. IgA concentrations were comparable for both groups during the first week of life (1.2 
and 0.6 mg/dl, respectively). After discharge Ballow et al. (12) followed 43 preterm infants 
until ten months chronological age and observed a significantly higher incidence of 
infections compared to 41 term infants (p = 0.04). In another study the level of maternal 
antibody required to protect neonates against early-onset disease caused by goup-B 
streptococci (GBS) type Ia was estimated (15). Levels of maternal serum IgG GBS Ia 
antibodies of 45 neonates with early onset disease case caused by GBS Ia and 319 control 
subjects (neonates colonized by GBS Ia but without early-onset disease) born at ≥34 weeks 
gestation were compared. The probability of developing infection declined with increasing 
maternal levels of IgG GBS Ia antibody (P <.03). Neonates whose mothers had levels of IgG 
GBS Ia antibody ≥5 mg/mL had an 88% lower risk (95% confidence interval, 7%–98%) of 
developing type-specific early-onset disease, compared with those whose mothers had 
levels <0.5 mg/mL (13). 
Yang et al. (14) studied the mechanism of bacterial opsonization by intravenous immune 
globulin (IVIG) complement consumption and polymorphonuclear leukocyte membrane 
receptor mediated phagocytosis of Staphylococcus epidermidis, Klebsiella pneumoniae, and 
groups A and B streptococci. IGIV alone did not consume complement and showed no 
opsonic activity by itself for these organisms. When these bacteria were preopsonized in 
intravenous immune globulin, significant amounts of complement were consumed (44%-
94%) and the uptake and killing of bacteria occurred. An important finding was the fact that 
in vitro opsonic activity of IGIV for these organisms was significantly correlated with the 
amount of complement consumed by the IVIG – opsonised bacteria. The in vivo protective 
efficacy of IVIG also appeared to be directly associated with its ability to activate and 
consume complement. The higher the titers of the IVIG preparation are (higher than 200 
units:ml) the more opsonic activity has been shown towards slime-producing S. epidermidis 
(15). Administered as a prophylactic agent to low-birth weight (lower than 1700 g) preterm 
neonates immediately after birth revealed significantly higher specific IgG in blood sera 
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compared to controls with an effect even lasting ten days after the last infusion. These 
results suggest that specific IgG titers might be well indicative of its opsonic activity against 
slime-producing S. epidermidis and might protect against bacteraemia. 
The complement-inhibitory activity of different IVIG preparations was assessed in vitro by 
measurement of the blocking of C1q-, C4-, and C3 deposition on solid-phase aggregated 
rabbit IgG by enzyme-linked immunosorbent assay (16). Results showed that IgM 
enrichment of IVIG preparations enhances their effect to prevent the inflammatory effects of 
complement activation. No IgG preparation negatively affected in vitro phagocytosis of 
Escherichia coli by human granulocytes. 
The mechanisms and effects of IVIGs are summarized in table 1 according to the description 
of Ballow (17). 
 
 Fc receptor blockade of reticulo-endothelial cell system and mononuclear phagocytes 
 Competitive interaction of IVIG with anti-platelet antibodies for FC receptor 
 Soluble Fcγ receptors compete with membrane Fc receptors of the reticulo-
endothelial system 
 Modulation of Fc receptor expression or affinity 
 Immunomodulation 
 Enhancement of T cell suppressor function 
 Inhibit B cell function and/or antigen-processing cells via Fc receptor 
 Restoration of idiotype-antiidiotypic network 
 Modify complement-dependent immune damage to tissue and cells 
 Inhibit cytokine/interleukin production/action 
 “Neutralize” toxin superantigen 
 Soluble CD4 and CD8, soluble HLA Class II molecules that modulate antigen 
processing and/or T cell activation 
Table 1. Mechanisms of action of intravenous immune globulins (17) 
Similar to most immunoglobins, the transplacental transport of IgG from the mother to fetus 
begins around 32 weeks of gestational age and increases until term. Premature infants born 
prior to 32 weeks gestation have profound IgG deficiencies. The major function of IgG in 
host defense is to opsonize bacteria and neutralize viruses. Levels of postnatal IgG are often 
low due to insufficient production by the immature neonatal immune system and 
catabolism of maternal IgG. Opsonic activity is also type-specific; therefore humoral 
immunity transferred to the neonate will be insufficient if the mother does not have 
immunity to the specific pathogen (18).  
4. Immunoglobulins in neonates 
Immunotherapy was a common method of treatment of infectious diseases in the 
preantibiotic era with serotherapy being a popular approach to serious infections by use of 
antisera from large animals. This administration unfortunately was associated with the risk 
 
Immunoglobulins in the Prevention and Treatment of Neonatal Sepsis 85 
of anaphylaxis and serum sickness. Further on immune globulins obtained from pooled 
human plasma were used, but antibodies provided by these preparations always 
represented those common to the donor population, and intravenous injection of early 
human IgG preparations was complicated by severe allergic reactions (19). The next step 
was the purification of human immune globulins, and, currently there are multiple 
formulations of safe, pooled, human immunoglobulins tor the intravenous use. 
The mortality rate of the preterm infants with septicaemia decreased from 44% in the infants 
receiving only antibiotics to 8% in the infants treated by IVIG together with the same 
antibiotic following administration of IVIG to preterm neonates (0.3 g/day in neonates 
below 1000 g; 0.5 g/day in neonates over 1000 g for 6 consecutive days). The IVIG 
preparation was well-tolerated by all newborns, and no adverse events were observed by 
monitoring blood gas analysis, clinical examination, monitoring of respiration, pulse and 
body temperature. Follow-up at an average age of 2.5 years showed no evidence of harmful 
effects of IVIG treatment in the neonatal period (20).  
Cates et al. (21) evaluated the formation of specific and functional antibody in preterm 
infants born weighing less than 1500 g (mean 1088 g) and less than 32 weeks of gestational 
age (mean 28.8 weeks). In the presence of complement, the strain of coagulase negative 
staphylococcus used was opsonized by IgG antibody, and the strain of Escherichia coli by 
IgM. Geometric mean plasma levels of tetanus and diphtheria IgG antibody fell from birth 
to 4 months chronological age, but rose significantly by 9 months (approximately 2 months 
after the third dose of diphtheria, tetanus, pertussis vaccine). However, at 9 months they 
remained lower than the respective geometric mean levels in 9-month-old term infants. The 
preterm infants' mean plasma IgG staphylococcal opsonic activity fell from birth to 2.5 
months, but by 9 months was comparable to that of term infants of the same age. Mean IgM 
opsonic activity for Escherichia coli was very low at birth in both preterm and term infants. 
It rose with chronological age, correlating with the rise in total IgM by 9 months the mean 
preterm and term infants' levels of IgM opsonic activity for E. coli were comparable. 
Sasidharan (22) studied serially IgG levels postnatally in 42 infants of very low birth weight 
with gestational ages ranging from 23 to 31 weeks (mean birth weight 971 g). Eighteen 
infants (43%) had IgG levels of less than 100 mg/dl by a mean postnatal age of 71 days. The 
lowest level was found in a 700g infant with 22 mg/dl. In sixteen cases having cord blood 
IgG levels determined mean IgG values was 414 mg/dl. This had dropped to a mean of 140 
mg/dl by 57 days. As expected, the lowest IgG levels postnatally were a reflection of the 
degree of prematurity and the length of postnatal age. 
To proof the significance of low serum IgG and complement proteins in very low birth 
neonates Lassiter et al (23) measured serum IgG, C3, C4 and Factor B weekly by rate 
nephelometry in 15 neonates who developed proven nosocomial bacterial or candidal sepsis 
and 27 neonates who did not develop sepsis. In the first and second week of life the serum 
IgG of infected neonates was significantly lower (mean 295 and 270 mg/dl compared to 440 
and 473 mg/dl, respectively. If the IgG was less than 350 mg/dl in the first week or less than 
230 mg/dl in the second week, the relative risk of acquiring sepsis was greater than or equal 
to 5 (CI 95% 1.7 to 11.2).  
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Amato et al. (24) investigated serial IgG and IgM serum levels during the neonatal period in 
two groups of non-septic, preterm infants treated prophylactic with IVIG. Twenty-two very 
low birth weight infants (mean gestational age 31.8 weeks and mean birth weight 1265 g 
with a range of 1001 - 1500g) and 12 extremely low birth weight infants < 1000g (mean 
gestational age 28.6 weeks and mean birth weight 910g) received at random three standard 
doses of IVIG (0.5 g/kg/day) or IVIGAM (IgM enriched preparation) (5 ml/kg/day). IgG and 
IgM concentrations were assayed by rate nephelometry before treatment and at day 3, 5, 7, 
14 and 28 of life. At any time IgG levels were higher in the IVIG very low birth weight group 
and no difference was observed in the extremely low birth weight group. IgM levels were 
higher at day 3 and 5 in the IVIGAM very low birth weight group and until day 7 in the 
extremely low birth weight group. The authors concluded that their findings indicate a wide 
range of IgG and IgM kinetics in the healthy premature infant.  
Supplementation of the preterm serum with either intravenous immunoglobulin or IgM-
enriched immunoglobulin did not change the results of phagocytosis rates (percentage of 
neutrophils phagocytosing group B streptococci in vitro in infants < 32 weeks of gestation 
and adult controls) significantly (25).  
In a rat model marked neutropenia, complete depletion of the neutrophil storage pool, and 
death within 48 hours were observed in newborn rats intrapulmonically inoculated with 
type III group B streptococci (26). Intraperitoneal administration of 225 mg of IVIG 
immediately after intrapulmonic inoculation of GBS significantly lessened the degree of 
neutropenia and prevented depletion of the neutrophil storage pool and death. No effect of 
IVIG on neutrophil production was observed in vitro or in vivo in normal neonatal rats 
injected with IVIG. IVIG, however, markedly hastened release of neutrophils from the 
reserves into the blood and hastened the arrival of neutrophils at the site of the bacterial 
injection. Specific antibody to GBS, as opposed to a nonspecific IgG effect, appeared to be 
responsible for the improvements in neutrophils kinetics and for survival of the animals. 
In animal experiments following administration of IVIGAM endotoxemia was induced by 
intraperitoneal inoculation of a sublethal dose of Escherichia coli and subsequent 
intravenous administration of an antimicrobial agent (27). Prophylactic administration of 
IVIGAM was found to significantly attenuate the antibiotic-induced increase in endotoxin 
activity as compared to the albumin control group. These experimental results suggested 
that in endotoxaemia the polyclonal immunoglobulin preparation had a prophylactic 
protective effect on the acute phase responses and reduced the cardiodepressant effects of 
Escherichia coli septicaemia. 
The pharmacokinetics and safety of IVIG were examined in thirty neonates with suspected 
sepsis who were randomly assigned either to a treatment (receiving either 250, or 500, or 
1,000 mg/kg of IVIG plus antibiotics) or control (antibiotics alone) group (28). The 500 mg/kg 
dose produced a rise in total IgG for greater than 8 and in group B streptococcus type-
specific IgG for greater than 4-14 days. The type-specific antibody elevation varied with the 
amount of pathogen-specific antibody and dose of IVIG. Pharmacokinetic analysis 
suggested a biphasic elimination curve and a terminal elimination half-life of 24.2 days. No 
toxicity was observed (28).  
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Prophylactic IVIG at a dose of 0.5 g/kg/day was given prospectively in 28 healthy preterm 
infants with a mean gestational age of 29.4 weeks and weight of 1,387g when they were 3-10 
days old (29). Urine samples of the neonates were obtained for analysis on days 1, 2 and 3 
following IVIG administration as well as 1 day before; and urinary nitrite levels were 2.77 
+/- 1.66 µmol/mmol creatinine before IVIG administration; 4.33 +/- 3.88 µmol/mmol 
creatinine on the 1st; 3.77 +/- 2.73 µmol/mmol creatinine on the 2nd, and 3.64 +/- 3.28 
µmol/mmol creatinine on the 3rd day. The increase of urinary nitrite levels was significant 
between before and after IVIG administration, thereafter levels did not differ significantly, 
suggesting that endogenous NO formation might play an important role in both the 
therapeutic and adverse effects of IVIG (29). 
5. Use of immunoglobulins in the treatment of neonatal sepsis 
Polyvalent immunoglobulin preparations are widely used as adjunctive therapy for sepsis 
or septic shock, but their efficacy is still a matter of debate. In 2007 Kreymann et al. (30) 
conducted a systematic review summarizing data on adults and neonates separately. In 
neonates, 12 trials (31-42) involving 710 patients were published. The estimate of the pooled 
effect on mortality was RR = 0.56 (95% CI 0.42– 0.74, p <.0001). Five studies (32,35,37,39,41) 
involving 352 patients were performed with the IgGAM preparation. The range of the 
cumulative dose of IgG was 0.57– 0.76 g/kg birth weight plus 0.09–0.12 g/kg birth weight 
IgA and 0.09–0.12 g/kg birth weight IgM. In this subgroup, the estimate of the pooled effect 
was RR = 0.50 (95% CI 0.34–0.73), equivalent to a 50% relative reduction in mortality (p < 
.0003). The study effects were comparable, and the test of heterogeneity was not significant. 
The study of El Nawawy (32) reported a significant reduction of mortality, the other four a 
positive trend (35,37,39,41). Polyvalent immunoglobulin preparations containing only IgG 
were evaluated in seven trials (31,33,34,36,38,40,42) involving 358 patients. The cumulative 
dose of IgG was 0.5–3 g/kg birth weight. The estimate of the pooled effect for this subgroup 
was RR = 0.63 (95% CI 0.42– 0.96), equivalent to a 37% relative reduction in mortality (p < 
.03). The test of heterogeneity was not significant. One study (38) reported a significant 
reduction in mortality, three studies reported a positive trend (31,33,42), and two studies 
(34,40) showed no effect. One trial (36) showed a duplication of mortality; one neonate died 
in the control group and two in the treatment group. Comparing the two treatment 
modalities, a small and insignificant difference in favour of IgGAM was observed (z = 0.80, 
p ≤ .42). Kreymann et al. (30) found a negative correlation with the severity of illness (as 
measured by the mortality of the control groups) in neonates; however, this held true only 
when the results reported by Chen (36) were included: In this study, an exceptionally low 
mortality in the control group was observed (1 of 28, respectively, 3.6%), which was doubled 
in the treatment group (2 of 28, respectively, 7.1%). If these results were omitted, the 
correlation lost significance. Additionally the authors found no correlation with the dosage 
of immunoglobulins administered. 
In adults and children, Kreymann et al. (30) found a strong trend in favour of IgGAM over 
IgG preparations with a 34% and 15% reduction of the risk to die, respectively, compared to 
an even higher 50% and 37% relative reduction of mortality in neonates, respectively. In 
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neonates and especially preterm infants, therapy with polyclonal immunoglobulins should 
be understood much more as a substitutional therapy than as an adjunctive therapy as for 
adults or older children (43). Comparing the two treatment modalities (IgGAM vs. IgG) in 
neonates, Kreymann et al. (30) only found a slight difference without statistical significance. 
A major limitation of this meta-analysis is the inclusion of the study of El Nawawy (32), who 
originally included infants of 1 to 24 months of age hospitalized at a pediatric intensive care 
unit, of which 50 were proven septic patients. This study strongly influenced study results 
favouring immunoglobulin therapy. 
Ohlsson and Lacy (44) recently reviewed IVIG for suspected or subsequently proven 
infection in neonates including randomized or quasi-randomized controlled trials 
comparing IVIG treatment to placebo or no intervention in newborn infants below 28 days 
of age. They found 10 studies meeting their inclusion criteria that differed to the above 
mentioned analysis (30) by additional including the small study of Christensen et al. (45) 
and a new study by Ahmend et al. (46) and not including the studies by El Nawawy (32), 
Gökalp (38), and Gunes (31).The results showed a statistically significant reduction in 
mortality in cases of proven and also of suspected infection with a NNT of 10 infants (95% 
CI; 6, 33) to avoid one death.  
IVIG preparations with high concentrations of antibodies to bacteria that are commonly 
isolated from neonates in specific local settings or geographical areas may be more effective 
in reducing adverse outcomes (44). However, the use of antistaphylococcal 
immunoglobulins to prevent staphylococcal infection in very low birth weight infants has 
recently been reviewed and is currently not recommended (47). 
A very recent study published by the International Neonatal Immunotherapy Study (INIS) 
Collaborative group enrolled 3493 infants with birth weight less than 1500g receiving 
antibiotics for suspected or proven serious infection and randomly assigned them to receive 
two infusions of either IgG immune globulin (at a dose of 500 mg per kilogram of body 
weight) or matching placebo 48 hours apart (48). The researchers found no significant 
between-group difference in the rates of death or major disability at the age of two years (39 
and 39%, respectively). Similarly, there were no significant differences in the rates of 
secondary outcomes including the incidence of subsequent sepsis episodes. In the 2-years 
follow-up of the study participants there were no differences in the rates of major or non-
major disability or of adverse events. Thus, IgG IVIG was not found to be helpful in 
diminishing the risk of major complications or adverse outcomes in neonates with suspected 
or proven sepsis. The duration of hospital stay also did not differ between groups (48). 
The clinical efficacy of IgM-enriched IVIG (currently there is only one preparation available, 
Pentaglobin®) has been reviewed by Norrby-Teglund et al. (49) for both adult and 
paediatric/neonatal patients. The authors concluded that patients most likely to benefit are 
Gram-negative septic shock patients. Therefore it is important to emphasize that selection of 
study patients as well as microbiological aetiology are of high relevance affecting the 
efficacy of IVIG. 
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6. Use of immunoglobulins in the prevention of neonatal sepsis 
There have been published a lot of studies and reviews on the preventive use of IVIG in 
preterm infants and I herewith report (“pars pro toto”) two multicenter randomized, 
double-blind, placebo-controlled trial published early in the New England Journal of 
Medicine (50,51) with divergent results and the latest Cochrane Review (52). 
Baker et al. (50) included 588 infants with a birth weight of 500 - 1750 g and age of 3 - 7 days 
from six centres in the U.S. between 1987 and 1988. The trial was randomized, double-blind, 
placebo-controlled with 287 infants having received 500 mg/kg of IVIG at enrolment (age 3 
to 7 days), one week later, and then every 14 days until a total of five infusions had been 
given or until hospital discharge, whichever came first, and 297 controls having received an 
equal volume of a sterile solution of 5 % albumin and 0.9 % sodium chloride. Outcomes 
included proven infection - clinical findings of sepsis and at least one of the following: a 
positive blood culture of either bacteria or fungi (the isolation of a pathogen from a 
normally sterile other body site or urine obtained by suprapubic or bladder catheterization, 
or the isolation of virus from an infant with clinical deterioration), necrotizing enterocolitis 
stage II or III, intraventricular haemorrhage grade 1 to 4, bronchopulmonary dysplasia, 
death, and total days in hospital. There were 50 episodes of sepsis among 287 infants (17.4%) 
in the IVIG group and 75 episodes of sepsis among 297 infants (25.3%) in the placebo group. 
The cumulative relative risk reduction was 0.7 (CI 95% 0.5-0.9). 
In a prospective, multicenter, two-phase controlled trial, Fanaroff et al. (51) stratified 2416 
infants according to birth weight (501 to 1000 g and 1001 to 1500 g) and randomly assigned 
to an IVIG (n = 1204) or a control group (n = 1212). Control infants were given placebo 
infusions during phase 1 of the study (n = 623) but were not given any infusions during 
phase 2 (n = 589). Infants weighing 501 to 1000 g at birth were given 900 mg of immune 
globulin per kilogram of body weight, and infants weighing 1001 to 1500 g at birth were 
given a dose of 700 mg per kilogram. The immune globulin infusions were repeated every 
14 days until the infants weighed 1800 g, were transferred to another center, died, or were 
sent home from the hospital. Nosocomial infections of the blood, meninges, or urinary tract 
occurred in 439 of the 2416 infants (18.2 %): 208 (17.3 %) in the immune globulin group and 
231 (19.1%) in the control group (relative risk, 0.91; CI 95% 0.77 to 1.08). Septicemia occurred 
in 15.5% of the immune globulin recipients and 17.2% of the controls. The predominant 
organisms included gram-positive cocci (53%), gram-negative bacilli (22.4%), and candida 
species (16%). Adverse reactions were rarely observed during the infusions. Immune 
globulin therapy had no effect on respiratory distress syndrome, bronchopulmonary 
dysplasia, intracranial hemorrhage, the duration of hospitalization, or mortality. The 
incidence of necrotizing enterocolitis was 12% in the immune globulin group and 9.5” in the 
control group. Thus, the authors concluded that the prophylactic use of IVIG failed to 
reduce the incidence of hospital-acquired infections in very-low-birth-weight infants (51). 
The prophylactic administration of intravenous immunoglobulins (IVIG) to prevent 
nosocomial infections has been studied in >5,000 neonates from 19 studies enrolled in 
randomised controlled trials (52). The results of these meta-analyses showed a statistically 
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significant reduction in sepsis (number needed to treat – NNT - 36) and/or any serious 
infection (NNT 31), but no reduction in mortality from infection. The reviewers concluded 
that IVIG administration resulted in a 3% reduction in sepsis and a 4% reduction in any 
serious infection of one or more episodes. Nevertheless it was not associated with 
reductions in other important outcomes including necrotizing enterocolitis intraventricular 
haemorrhage, or length of hospital stay. Most importantly, IVIG administration did not 
have any significant effect on mortality from any cause or from infections. There were no 
adverse events observed to be associated with prophylactic use of IVIG. From a clinical 
perspective a 3-4% reduction in nosocomial infections without a reduction in mortality or 
other important clinical outcomes might be of marginal importance and has to be 
outweighed by the costs and the values assigned to the clinical outcomes (52). This 
Cochrane review ends with the statement that there is no justification for further 
randomized trials testing the efficacy of previously studied IVIG preparations to reduce 
nosocomial infections in preterm and/or low birth weight infants. In contrast, these results 
should encourage basic scientists and clinicians to pursue other avenues to prevent 
nosocomial infections (52). 
7. Conclusions 
There is a rational to use of IVIG in either adjunctive treatment neonatal sepsis or in the 
prevention by low immunoglobulin levels associated with the immature innate immune 
system of preterm infants. Studies so far revealed a benefit for IgM enriched IVIG in the use 
as adjunctive sepsis treatment by an overall significantly reduced mortality rate. 
Prophylactic use of IVIG resulted in marginally reduced rates of nosocomial infections, and 
other non-invasive approaches like use of lactoferrin (53) and/or probiotics (54) seem to be 
more promising in the prevention of nosocomial infections in very low birth weight infants. 
Author details 
Elisabeth Resch and Bernhard Resch 
Research Unit for Neonatal Infectious Diseases and Epidemiology, Division of Neonatology, 
Department of Pediatrics, Medical University of Graz, Austria 
8. References 
[1] Escobar GJ. The neonatal ‘‘sepsis work-up’’: personal reflections on the development of 
an evidence-based approach toward newborn infections in a managed care 
organization. Pediatrics 1999;103:360–733. 
[2] Issacs D, Moxon ER. Handbook of neonatal infections, a practical guide. WB Saunders, 
London, Edinburgh, New York, Philadelphia, Sydney, Tokio1999, pp1-13 
[3] Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B, Higgins RD; 
National Institute of Child Health and Human Development Neonatal Research 
 
Immunoglobulins in the Prevention and Treatment of Neonatal Sepsis 91 
Network. Neurodevelopmental and growth impairment among extremely low-birth-
weight infants with neonatal infection. JAMA 2004;292:2357-2365. 
[4] Gerdes JS. Diagnosis and management of bacterial infections in the neonate. Pediatr 
Clin North Am 2004;51:939-959 
[5] Lawn JE, Cousens S, Zupan J; Lancet Neonatal Survival Steering Team. 4 million 
neonatal deaths: when? Where? Why? Lancet 2005;365:891-900. 
[6] Shaw CK, Thapalial A, Shaw P, Malla K. Intravenous immunoglobulins and 
haematopoietic growth factors in the prevention and treatment of neonatal sepsis: 
ground reality or glorified myths? Int J Clin Pract 2007;61:482–487 
[7] Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: 
definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 
2005;6:2-8. 
[8] Wynn JL, Wong HR. Pathophysiology and treatment of septic shock in neonates. Clin 
Perinatol 2010;37:439-479 
[9] Hofer N, Zacharias E, Müller W, Resch B. Performance of the definitions of the systemic 
inflammatory response syndrome and sepsis in neonates. J Perinat Med 2012 Jun 
14;0(0):1-4. doi: 10.1515/jpm-2011-0308. 
[10] Baker CJ, Edwards MD, Kasper DL. Role of Antibody to Native Type III Polysaccharide 
of Group B Streptococcus in Infant Infection. Pediatrics 1981;68:544 -549 
[11] Jenson HB, Pollock BH. Meta-analyses of the Effectiveness of Intravenous Immune 
Globulin for Prevention and Treatment of Neonatal Sepsis. Pediatrics 1997;99: e2 doi: 
10.1542/peds.99.2.e2 
[12] Ballow M, Cates KL, Rowe JC, Goetz C, Desbonnet C. Development of the immune 
system in very low birth weight (less than 1500 g) premature infants: concentrations of 
plasma immunoglobulins and patterns of infections. Pediatr Res 1986;20:899-904. 
[13] Lin FYC, Philips III JB, Azimi PH, Weisman LE, Clark P, Rhoads GG, Regan J, 
Concepcion NF, Frasch CE, Troendle J, Brenner RA, Gray BM, Bhushan, Fitzgerald G, 
Moye P, Clemens JD. Level of maternal antibody required to protect neonates against 
early-onset disease caused by group b streptococcus type Ia: a multicenter, 
seroepidemiology study. J Infect Dis 2001;184:1022–1028 
[14] Yang KD, Bathras JM, Shigeoka AO, James J, Pincus SH, Hill HR. Mechanisms of 
bacterial opsonization by immune globulin intravenous: correlation of complement 
consumption with opsonic activity and protective efficacy. J Infect Dis 1989;159:701-707 
[15] Lamari F. Determination of slime-producing S. epidermidis specific antibodies in 
human immunoglobulin preparations and blood sera by an enzyme immunoassay. 
Correlation of antibody titers with opsonic activity and application to preterm neonates. 
J Pharm Biomed Ana 2000;23:363–374 
[16] Rieben R, Roos A, Muizert Y, Tinguely C, Gerritsen AF, Daha MR. Immunoglobulin M-
Enriched Human Intravenous Immunoglobulin Prevents Complement Activation In 
Vitro and In Vivo in a Rat Model of Acute Inflammation. Blood 1999 93: 942-951 
[17] Ballow M. Mechanisms of action of intravenous immune serum globulin therapy. 
Pediatr Infect Dis J 1994;13:806-811 
 Neonatal Bacterial Infection 92 
[18] Melvan JN, Bagby GJ, Welsh DA, Nelson S, Zhang P. Neonatal Sepsis and Neutrophil 
Insufficiencies. Int Rev Immunol. 2010; 29: 315–348 
[19] Kliegman RM, Clapp DW. Rational principles for immunoglobulin prophylaxis and 
therapy of neonatal infections. Clin Perinatol 1991;18:303-324. 
[20] von Muralt G, Sidiropoulos D. Prenatal and postnatal prophylaxis of infections in 
preterm neonates. Pediatr Infect Dis J 1988;7(5 Suppl):S72-78. 
[21] Cates KL, Goetz C, Rosenberg N, Pantschenko A, Rowe JC, Ballow M. Longitudinal 
development of specific and functional antibody in very low birth weight premature 
infants. Pediatr Res 1988;23:14-22. 
[22] Sasidharan P. Postnatal IgG levels in very-low-birth-weight infants. Preliminary 
observations. Clin Pediatr (Phila) 1988;27:271-274. 
[23] Lassiter HA, Tanner JE, Cost KM, Steger S, Vogel RL. Diminished IgG, but not 
complement C3 or C4 or factor B, precedes nosocomial bacterial sepsis in very low birth 
weight neonates. Pediatr Infect Dis J 1991;10:663-668. 
[24] Amato M, Hüppi P, Imbach P, Llanto A, Bürgi W. Serial IgG and IgM serum levels after 
infusion of different Ig-preparations (IgG or IgM-enriched) in preterm infants. Pediatr 
Allergy Immunol. 1993 Nov;4(4):217-20. 
[25] Bialek R, Bartmann P. Is there an effect of immunoglobulins and G-CSF on neutrophil 
phagocytic activity in preterm infants? Infection 1998;26:375-378. 
[26] Redd H, Christensen RD, Fischer GW. Circulating and storage neutrophils in septic 
neonatal rats treated with immune globulin. J Infect Dis. 1988;157:705-712. 
[27] Oesser S, Schulze C, Seifert J. Protective capacity of a IgM/IgA-enriched polyclonal 
immunoglobulin-G preparation in endotoxemia. Res Exp Med (Berl) 1999;198:325-339. 
[28] Weisman LE, Fischer GW, Marinelli P, Hemming VG, Pierce JR, Golden SM, Peck CC. 
Pharmacokinetics of intravenous immunoglobulin in neonates. Vox Sang 1989;57:243-
248. 
[29] Özkan H, Uzuner N, Ören H, Çabuk N, Islekel H. Urinary nitrite excretion after 
prophylactic intravenous immunoglobulin in premature infants. Biol Neonate 
2000;77:101-104 
[30] Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as 
adjunctive therapy for sepsis or septic shock. Crit Care Med 2007;35:2677-2685 
[31] Gunes T, Koklu E, Buyukkayhan D, Kurtoglu S, Karakukcu M, Patiroglu T. Exchange 
transfusion or intravenous immunoglobulin therapy as an adjunct to antibiotics for 
neonatal sepsis in developing countries: A pilot study. Ann Trop Paediatr 2006; 26:39–
42 
[32] El Nawawy A, El Kinany H, Hamdy El-Sayed M, Boshra N. Intravenous polyclonal 
immunoglobulin administration to sepsis syndrome patients: A prospective study in a 
pediatric intensive care unit. J Trop Pediatr 2005; 51:271–278 
[33] Weisman LE, Stoll BJ, Kueser TJ, Rubio TT, Frank CG, Heiman HS, Subramanian KN, 
Hankins CT, Anthony BF, Cruess DF, et al. Intravenous immune globulin therapy for 
early- onset sepsis in premature neonates. J Pediatr 1992; 121:434–443 
 
Immunoglobulins in the Prevention and Treatment of Neonatal Sepsis 93 
[34] Shenoi A, Nagesh NK, Maiya PP, Bhat SR, Subba Rao SD. Multicenter randomized 
placebo controlled trial of therapy with intravenous immunoglobulin in decreasing 
mortality due to neonatal sepsis. Indian Pediatr 1999; 36:1113–1118 
[35] Samantha S, Jalalu MP, Hegde RK, et al: Role of IgM enriched intravenous 
immunoglobulin as an adjuvant to antibiotics in neonatal sepsis. Karnataka Pediatr J 
1997; 1:1–6 
[36] Chen JY: Intravenous immunoglobulin in the treatment of full-term and premature 
newborns with sepsis. J Formos Med Assoc 1996; 95:839–844 
[37] Seitz RC, Turreson M, Grosse R, et al: Infusion of immunoglobulins for therapy of 
neonatal sepsis. Z Geburtshilfe Perinatol 1995; 199:288 
[38] Gökalp AS, Toksoy HB, Turkay S, Bakici MZ, Kaya R. Intravenous immunoglobulin in 
the treatment of Salmonella typhimurium infections in preterm neonates. Clin Pediatr 
(Phila) 1994; 33:349–352 
[39] Erdem G, Yurdakok M, Tekinalp G, Ersoy F. The use of IgM-enriched intravenous 
immunoglobulin for the treatment of neonatal sepsis in preterm infants. Turk J Pediatr 
1993; 35: 277–281 
[40] Mancilla-Ramirez J, Gonzalez-Yunes R, Castellanos-Cruz C, García-Roca P, Santos-
Preciado JI. Intravenous immunoglobulin in the treatment of neonatal septicemia. Bol 
Med Hosp Infant Mex 1992; 49:4–11 
[41] Haque KN, Zaidi MH, Bahakim H: IgMenriched intravenous immunoglobulin therapy 
in neonatal sepsis. Am J Dis Child 1988; 142:1293–1296 
[42] Sidiropoulos D, Böhme U, von Muralt G, Morell A, Barandun S. Substitution of 
immunoglobulins for the treatment of neonatal sepsis. Schweiz Med Wochenschr 1981; 
111:1649–1655 
[43] Bell SG: Immunomodulation, part III: Intravenous immunoglobulin. Neonatal Netw 
2006; 25:213–221 
[44] Ohlsson A, Lacy J. Intravenous immunoglobulin for suspected or subsequently proven 
infection in neonates. Cochrane Database of Systematic Reviews 2010, Issue 3. Art. No.: 
CD001239. DOI: 10.1002/14651858.CD001239.pub3.  
[45] Christensen RD, Brown MS, Hall DC, Lassiter HA, Hill HR. Effect of neutrophil kinetics 
and serum opsonic capacity of intravenous administration of immune globulin to 
neonates with clinical signs of early-onset sepsis. Journal of Pediatrics 1991;118: 606–
614. 
[46] Ahmed SS, Chowdhury MAKA, Hoque MM, Begum D, Ahmed ASMNU. Role of 
intravenous immunoglobulin (IVIG) as an adjuvant in the treatment of neonatal sepsis 
in preterm babies. Journal of Bangladesh College of Physicians and Surgeons 
2006;24:97–104. 
[47] Shah PS, Kaufman DA. Antistaphyloccoccal immunoglobulins to prevent 
staphylococcal infection in very low birth weight infants. Cochrane Database of 
Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD006449.pub2] 
[48] INIS Collaborative Group. Brocklehurst P, Farrell B, King A, Juszczak E, Darlow B, 
Haque K, Salt A, Stenson B, Tarnow-Mordi W. Treatment of neonatal sepsis with 
intravenous immune globulinN Engl J Med 2011;365:1201-1211. 
 Neonatal Bacterial Infection 94 
[49] Norrby-Teglund A, Haque KN, L. Hammarström L. Intravenous polyclonal IgM-
enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to 
microbiological aetiology and severity of sepsis. Journal of Internal Medicine 2006; 260: 
509–516 
[50] Baker CJ, Melish ME, Hall RT, et al. Intravenous immune globulin for the prevention of 
nosocomial infection in low-birth-weight neonates. New Engl JMed 1992;327:213–219. 
[51] Fanaroff AA, Korones SB, Wright LL, Wright EC, Poland RL, Bauer CB, Tyson JE, 
Philips JB 3rd, Edwards W, Lucey JF, et al. A controlled trial of intravenous immune 
globulin to reduce nosocomial infections in very-low-birth-weight infants. National 
Institute of Child Health and Human Development Neonatal Research Network. New 
Engl J Med 1994;330(:1107-13. 
[52] Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm 
and/or low-birth-weight infants. Cochrane Database Syst Rev 2004;(1):CD000361 
[53] Manzoni P, Rinaldi M, Cattani S, Pugni L, Romeo MG, Messner H, Stolfi I, Decembrino 
L, Laforgia N, Vagnarelli F, Memo L, Bordignon L, Saia OS, Maule M, Gallo E, Mostert 
M, Magnani C, Quercia M, Bollani L, Pedicino R, Renzullo L, Betta P, Mosca F, Ferrari F, 
Magaldi R, Stronati M, Farina D; Italian Task Force for the Study and Prevention of 
Neonatal Fungal Infections, Italian Society of Neonatology. Bovine lactoferrin 
supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: 
a randomized trial. JAMA 2009;302:1421-1428. 
[54] Alfaleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotizing 
enterocolitis in preterm infants. Cochrane Database Syst Rev 2011 Mar 16;(3):CD005496. 
